The earnings call highlights significant progress in clinical trials and strategic partnerships for global market expansion, alongside a strong financial position. However, there are challenges in sales fluctuations and market penetration in the WHIM syndrome segment. On balance, the positive developments and growth potential outweigh the current sales challenges.

Company Guidance -

Q3 2025

In the first quarter of 2025, X4 Pharmaceuticals reported significant progress, with a focus on mavorixafor's development for chronic neutropenia (CN) and WHIM syndrome. The 4WARD trial, a pivotal Phase III study, is underway in over 20 countries, targeting patients with moderate to severe CN, defined as an ANC below 1000 cells per microliter and experiencing multiple infections over 12 months. The trial aims to demonstrate statistically significant ANC responses and reduced infection rates, with a robust powering of over 95% for ANC response and 90% for infection rate results. X4 expects full enrollment by late 2025 and top-line data in 2026. Additionally, the company noted cumulative XOLREMDI sales of $3.5 million since its mid-2024 launch, with new patients constituting 40% of the treated population. X4 also expanded mavorixafor's potential reach through partnerships in Europe, Australia, New Zealand, and the MENA region and anticipates EMA approval by early 2026. The company ended the quarter with nearly $90 million in cash, expecting to sustain operations into the first half of 2026.

Significant Progress in Clinical Trials

X4 Pharmaceuticals has advanced the 4WARD trial, a global pivotal Phase III clinical trial for mavorixafor in chronic neutropenia (CN), with over 90% of trial sites activated and enrollment underway in over 20 countries. The trial is powered at greater than 95% for the ANC response endpoint and expects full enrollment by Q3/Q4 2025.

Patent Allowance for Mavorixafor

The US Patent Office has issued a notice of allowance for the use of mavorixafor in treating severe chronic idiopathic and autoimmune neutropenia, with the patent expected to expire in March 2041.

Partnerships for Global Expansion

X4 has completed two international partnerships: one with Norgine for commercialization in Europe, Australia, and New Zealand, and another with taiba rare for the Middle East and North Africa (MENA) region.

Strong Financial Position

X4 ended Q1 2025 with nearly $90 million in cash, supporting operations into the first half of 2026. The company reported a net income due to $28 million in license revenue from Norgine and a gain of $10.8 million on Class C warrants.

X4 Pharmaceuticals (XFOR) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

XFOR Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Nov 06, 2025	2025 (Q3)	- / -	-5.4	―	―	―
Jul 31, 2025	2025 (Q2)	-3.94 / -	13.5	―	―	―
May 01, 2025	2025 (Q1)	-3.55 / 0.04	-7.8	100.51% (+7.84)
Mar 25, 2025	2024 (Q4)	-5.28 / -6.00	-3	-100.00% (-3.00)	―
Nov 13, 2024	2024 (Q3)	-5.14 / -5.40	-0.3	-1700.00% (-5.10)
Aug 08, 2024	2024 (Q2)	-0.21 / 13.50	-9.9	236.36% (+23.40)	―
May 07, 2024	2024 (Q1)	-4.63 / -7.80	-4.8	-62.50% (-3.00)	―
Mar 21, 2024	2023 (Q4)	-4.37 / -3.00	-8.7	65.52% (+5.70)	―
Nov 09, 2023	2023 (Q3)	-4.47 / -0.30	-7.8	96.15% (+7.50)
Aug 10, 2023	2023 (Q2)	-4.87 / -9.90	-18	45.00% (+8.10)	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

XFOR Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Jul 31, 2025	$1.77	$1.68	-5.08%
May 01, 2025	$4.31	$3.75	-12.99%
Mar 25, 2025	$8.85	$7.78	-12.09%
Nov 13, 2024	$17.76	$8.32	-53.15%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does X4 Pharmaceuticals (XFOR) report earnings?

X4 Pharmaceuticals (XFOR) is schdueled to report earning on Nov 06, 2025, Before Open (Confirmed).

What is X4 Pharmaceuticals (XFOR) earnings time?

X4 Pharmaceuticals (XFOR) earnings time is at Nov 06, 2025, Before Open (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is XFOR EPS forecast?

Currently, no data Available

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing